BRUKINSA leads the charge, but patents and pipelines matter
- Q2 2026 total global revenue was $1.7 billion, up 30% from the prior year.
- BRUKINSA produced over $1.2 billion in Q2 2026 revenue and remains the core engine.
- The pipeline is advancing, highlighted by FDA approval of BEQALZI and success in the MANGROVE study.
- The CELESTIAL-301 trial missed a key statistical marker, showing the risk in clinical trials.
- Generic challenges and lawsuits, including a challenge to BRUKINSA tablets, pose real risks.
A global leader facing clear hurdles
BeOne has built a global oncology business around BRUKINSA. The blood cancer therapy is the global revenue leader in the BTK inhibitor class. In Q2 2026, BRUKINSA global revenues reached over $1.2 billion, which helped push total company revenue to $1.7 billion, up 30% from the prior year.
The bull case focuses on growth and a maturing pipeline. BRUKINSA continues to win new patients, and the Phase III MANGROVE study positions it well as a frontline, chemo-free regimen in mantle cell lymphoma. BeOne also secured FDA approval for BEQALZI, adding another tool. The company plans to seek accelerated approval for a new BTK degrader, Tacabrutideg, in late 2026.
The bear case centers on the vulnerability of relying so heavily on one drug and the uncertainty of clinical data. Zydus has filed to produce a generic version of BRUKINSA tablets, and AbbVie has sued over trade secrets related to a pipeline asset. Additionally, the recent CELESTIAL-301 trial did not reach statistical superiority on an early endpoint, showing that not every combination study will yield a clear win.
Discover, build, and distribute globally
BeOne discovers, develops, and sells targeted cancer treatments. The company relies on its internal sales teams in major markets like the U.S. and Europe, and uses partnerships, such as its deal with Amgen, to sell in-licensed products in China.
Product sales drive the vast majority of revenue. In Q2 2026, total revenue reached $1.7 billion. BRUKINSA was the dominant source, but other drugs like TEVIMBRA and Amgen partnered products also contributed significantly. The U.S. is the largest market, generating nearly $900 million in Q2.
The model relies heavily on clinical success and patent protection. Cancer drug markets are highly competitive. Companies must constantly fund new trials to expand approvals and defend against generic or biosimilar drugs. As BeOne scales, legal challenges from generic makers and supply chain complexities across the U.S., China, and Europe become larger factors.
The core franchise and new bets
BRUKINSA
The primary revenue driver. It treats various blood cancers and generated over $1.2 billion globally in Q2 2026.
TEVIMBRA
An immuno-oncology drug approved for certain esophageal and gastric cancers, adding a second commercial pillar.
BEQALZI
A newly FDA-approved BCL-2 inhibitor for relapsed or refractory mantle cell lymphoma.
Sonrotoclax
A BCL2 inhibitor with early approvals in China. It is being tested in combinations aiming for fixed-time cancer treatments.
Tacabrutideg
A BTK degrader aiming for accelerated approval submission in late 2026.
Amgen in-licensed products
Products like XGEVA and BLINCYTO that generate meaningful sales in China through a strategic partnership.
Revenue depends heavily on one drug
Mix is based on Q2 2026 total revenues of $1.7 billion. BRUKINSA represents approximately 71% of total sales.
What could derail the story
Generic BRUKINSA tablet challenge
High impact · Medium oddsZydus filed an application seeking FDA approval for a generic version of BRUKINSA tablets, leading to a patent lawsuit in early 2026. A loss could shorten the protected life of BeOne's biggest drug.
AbbVie trade secret lawsuit
Medium impact · Medium oddsAbbVie claims BeOne misused trade secrets for the BGB-16673 BTK degrader program. Litigation can consume resources and potentially restrict a key pipeline asset.
Clinical trial setbacks
High impact · Medium oddsThe failure of the CELESTIAL-301 trial to hit early statistical superiority shows the risk in developing fixed-time treatment combinations. Missing data bars can limit market expansion.
Geopolitical supply chain stress
Medium impact · Medium oddsOperating across the U.S., China, and Europe exposes the company to tariffs and import controls. U.S. regulatory scrutiny on imported pharmaceuticals remains an ongoing concern.
Biosimilar competition for partnered drugs
Low impact · High oddsManagement noted incoming biosimilar competition for XGEVA within their Amgen partnered portfolio, which could compress sales growth in China.
In one breath
What does BeOne Medicines do?
BeOne Medicines discovers, develops, and sells targeted cancer treatments. Its most successful product is BRUKINSA, a therapy for blood cancers.
Why is BRUKINSA important?
BRUKINSA generated over $1.2 billion in Q2 2026, representing about 71% of total revenue. The company's financial success is heavily tied to this single drug.
What is the CELESTIAL-301 trial?
It is a study testing a new drug combination. The trial recently missed an early statistical marker, though it continues toward its main goal of tracking progression-free survival.
